Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

Completed

• Conditions: Acute Lymphoblastic Leukemia

• Registration Number: NCT01380587
• Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Brief Summary

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Detailed Description

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2011-06-22
• Study First Submitted QC: 2011-06-23
• Study First Posted: 2011-06-27
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Status Verified: 2013-08
• Last Update Submitted: 2013-08-26
• Last Update Posted: 2013-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion Criteria

• Patients with prior treatment with chemotherapeutic agents.
• Patients treated with immunosuppressants.
• Patients under 12 months old.
• Patients with a diagnosis or history of autoimmune diseases.
• Patients with a diagnosis or history of immunosuppressive diseases.
• Patients who do not agree to sign a Letter of Informed Consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of patients with poor prognosis and high levels of XCL1	3 months	Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
Number of patients with poor prognosis and high levels of cytokines	3 months	Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.

Trial Locations

Locations (1)

Hospital Universitario Dr. Jose E. Gonzalez UANL; 🇲🇽 Monterrey, Nuevo Leon, Mexico